See the possibilities for your patients.

RPGR Mutation Male: 36 years old

The Vista Clinical trial has completed enrollment. However, there may be other options for your XLRP patients.

LANDSCAPE clinical trial eligibility

pre-screening trial

Your patient may qualify to participate in the LANDSCAPE clinical trial, a phase 2 study evaluating an investigational gene therapy for the treatment of retinitis pigmentosa.
Patients must meet the following criteria:

  • Diagnosis of XLRP confirmed by a healthcare professional
  • Have a mutation in the RPGR gene confirmed by genetic testing
  • Male ages 12-50 years
  • Have best corrected visual acuity no better than 20/32 and no worse than 20/200 in BOTH eyes
Refer a patient for pre-screening Refer a patient for genetic testing
Healthcare provider brochure

See possibilities, not problems. Take the next step to find out more about resources available for you and your patients.

Clinical Trial Opportunities

Beacon Therapeutics is currently pre-screening male patients between the ages of 12-50 (inclusive) diagnosed with X-linked retinitis pigmentosa (XLRP) for the LANDSCAPE trial.

learn more

Genetic Testing Options

Genetic testing is critical to the diagnosis of patients with Inherited Retinal Disease. Learn more about the no-cost genetic testing that may be available for your patients.

learn more

Visionary science for life-changing cures

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

We have an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (dAMD) and another targeting cone-rod dystrophy (CRD).

Learn more at beacontx.com

To enter the site, please indicate that you are a Healthcare Professional